Evaluates the response rate, duration of response and toxic effects in previously untreated patients with unrespectable local-regional or metastatic carcinoma of the esophagus. Premedication; Starting dose of paclitaxel (Taxol); Median age of patients; Median number of courses; Total courses; Patients with complete or partial responses; Patients without responses.